Abhishek Gulati is currently Principal Scientist (Scientific Director), leading/supporting efforts in the Cardio-metabolic Diseases/Infectious Diseases/Vaccines/Immunology Therapeutic Area within the Quantitative Pharmacology and Pharmacometrics Department at Merck & Co., Inc.
Prior to joining Merck, he was Associate Director in the PKMS New Technologies Group within Clinical Pharmacology and Exploratory Development (CPED) at Astellas Pharma, where he was instrumental in establishing the Quantitative Systems Pharmacology Group within CPED. He led MIDD efforts in several clinical programs in the Immunology and Oncology/Immuno-oncology therapeutic areas.
Abhishek received his Ph.D. from University of Otago, New Zealand and completed Postdoctoral Fellowships at University of Otago and Division of Clinical Pharmacology, Indiana University, focusing on several modeling aspects in the cardiovascular, pulmonary and neuroscience therapeutic areas. He then worked at AbbVie on various clinical pharmacology studies supporting the launch of Mavyret, AbbVie's HCV Next Gen asset.
He has co-authored more than 20 publications in high-impact, peer-reviewed journals, given several presentations at national and international meetings and won several awards, including the Innovation in Communication Award by American Conference on Pharmacometrics. He serves on the Editorial Advisory Board of the Journal of Pharmacokinetics and Pharmacodynamics; co-chairs and is a member of several mechanistic modeling focused working groups within ISoP, AAPS and IQ Consortium.